The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia. [electronic resource]
Producer: 20110224Description: 5339-50 p. digitalISSN:- 1557-3265
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Benzamides
- Biomarkers, Pharmacological -- analysis
- Biomarkers, Tumor -- analysis
- Cohort Studies
- Cytogenetic Analysis
- Female
- Genotype
- Humans
- Imatinib Mesylate
- Interferon-gamma -- genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- diagnosis
- Male
- Middle Aged
- Molecular Diagnostic Techniques
- Piperazines -- therapeutic use
- Polymorphism, Single Nucleotide -- physiology
- Pyrimidines -- therapeutic use
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Validation Study
There are no comments on this title.
Log in to your account to post a comment.